Filorga, a distinguished French premium skincare brand, has long been recognized for its pioneering approach to integrating aesthetic medicine with at-home skincare solutions. Established in 1978 by Dr. Michel Tordjman, a physician with a deep interest in cell biology, Filorga initially focused on developing injectable solutions tailored exclusively for medical practitioners. Leveraging its expertise in aesthetic treatments, the brand later expanded into topical skincare products, enabling consumers to achieve professional-grade results in a home setting.
In a significant strategic development, Colgate-Palmolive acquired Laboratoires Filorga Cosmétiques in 2019 for approximately €1.5 billion (equivalent to roughly $1.69 billion). This acquisition represented Colgate-Palmolive’s largest investment in over 20 years, underscoring its intent to bolster its foothold in the expanding premium skincare market, diversifying beyond its established leadership in oral care.
Filorga’s product portfolio features notable anti-aging offerings, including the NCEF-Shot serum, Hydra-Hyal serum, and Time-Filler creams. Central to many of these formulations is the brand’s proprietary NCEF complex, a sophisticated blend of 50 active ingredients—such as vitamins, minerals, antioxidants, and coenzymes—designed to revitalize skin, enhance texture, and reduce visible signs of aging.
Presently, Filorga maintains a global presence across more than 60 countries, with a particularly robust market position in France, Italy, Spain, and Greater China. The brand continues to prioritize innovation, blending advanced scientific research with luxurious, high-performance formulations. Catering to both medical professionals and discerning consumers, Filorga solidifies its standing as a leader in scientifically validated, premium skincare solutions.
